Eczema, also known as atopic dermatitis, is a skin condition that affects nearly 18 million Americans. The signs and symptoms of eczema differ from person-to-person but may include symptoms like dry sensitive skin, itchiness, dark colored patches of skin, or areas of swelling.
On March 28th, the FDA approved Dupixent (dupilumab), the first biologic injection medication used to treat severe cases of eczema. In the past, Eczema treatments have only consisted of topical medications and steroid creams, so this new injection is a potential breakthrough for many people who have been suffering for years without treatment. Read our post here for more information about biologics.
What is atopic dermatitis?
Atopic dermatitis (eczema) is a long-term inflammatory skin disease characterized by dry, itchy skin. It usually affects babies and children, but the condition can carry over into adulthood.
Common symptoms of atopic dermatitis include red, scaly bumps and itchiness. These symptoms are exacerbated when patients itch the affected skin – as that can cause swelling, cracking, crusting, and “weeping” clear fluid.
What is Dupixent indicated for?
Dupixent is indicated for the treatment of adult patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies. Dupixent can be used with or without topical medications.
How is Dupixent to be used?
Dupixent is available as a single-dose pre-filled syringe to be administered under the guidance of a healthcare provider. However, after patients are trained in the subcutaneous injection technique by a healthcare provider, they may self-inject Dupixent.
The initial dose of Dupixent is 600 mg of the subcutaneous injection (two 300 ml syringes) followed by 300 mg injections every other week.
What are the common side effects associated with Dupixent?
Side effects include injection site reactions, cold sores, and eye and eyelid inflammation.
How can I save on Dupixent?
Like many other new biologics, Dupixent does not come cheap. Luckily, Sanofi has created the Dupixent MyWay program to help patients with injection training and guidance through the insurance process. This program also offers commercially eligible insured patients a $0 copay card for Dupixent. For more information about eligibility and to enroll, visit the Dupixent MyWay program website here, or call 1-844-387-2936.